Details of the Drug

General Information of Drug (ID: DM1MZAQ)

Drug Name
Zilovertamab vedotin
Synonyms MK-2140
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Phase 2/3 [1]
Drug Type
Antibody drug conjugate
Cross-matching ID
UNII
IZY9ZSI6FI
DrugBank ID
DB18457
TTD ID
D3YJZ7

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neurotrophic tyrosine kinase ROR1 (ROR1) TTDEJAU ROR1_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05139017) A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003). U.S.National Institutes of Health.
2 ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood. 2021 Jun 17;137(24):3365-3377.